Literature DB >> 27189655

Spina bifida.

Andrew J Copp1, N Scott Adzick2, Lyn S Chitty3, Jack M Fletcher4, Grayson N Holmbeck5, Gary M Shaw6.   

Abstract

Spina bifida is a birth defect in which the vertebral column is open, often with spinal cord involvement. The most clinically significant subtype is myelomeningocele (open spina bifida), which is a condition characterized by failure of the lumbosacral spinal neural tube to close during embryonic development. The exposed neural tissue degenerates in utero, resulting in neurological deficit that varies with the level of the lesion. Occurring in approximately 1 per 1,000 births worldwide, myelomeningocele is one of the most common congenital malformations, but its cause is largely unknown. The genetic component is estimated at 60-70%, but few causative genes have been identified to date, despite much information from mouse models. Non-genetic maternal risk factors include reduced folate intake, anticonvulsant therapy, diabetes mellitus and obesity. Primary prevention by periconceptional supplementation with folic acid has been demonstrated in clinical trials, leading to food fortification programmes in many countries. Prenatal diagnosis is achieved by ultrasonography, enabling women to seek termination of pregnancy. Individuals who survive to birth have their lesions closed surgically, with subsequent management of associated defects, including the Chiari II brain malformation, hydrocephalus, and urological and orthopaedic sequelae. Fetal surgical repair of myelomeningocele has been associated with improved early neurological outcome compared with postnatal operation. Myelomeningocele affects quality of life during childhood, adolescence and adulthood, posing a challenge for individuals, families and society as a whole. For an illustrated summary of this Primer, visit: http://go.nature.com/fK9XNa.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 27189655      PMCID: PMC4898641          DOI: 10.1038/nrdp.2015.7

Source DB:  PubMed          Journal:  Nat Rev Dis Primers        ISSN: 2056-676X            Impact factor:   52.329


  220 in total

1.  Congenital malformation and maternal occupational exposure to glycol ethers. Occupational Exposure and Congenital Malformations Working Group.

Authors:  S Cordier; A Bergeret; J Goujard; M C Ha; S Aymé; F Bianchi; E Calzolari; H E De Walle; R Knill-Jones; S Candela; I Dale; B Dananché; C de Vigan; J Fevotte; G Kiel; L Mandereau
Journal:  Epidemiology       Date:  1997-07       Impact factor: 4.822

2.  Cranial and cerebral signs in the diagnosis of spina bifida between 18 and 22 weeks of gestation: a German multicentre study.

Authors:  F Bahlmann; I Reinhard; T Schramm; A Geipel; U Gembruch; C S von Kaisenberg; R Schmitz; J Stupin; R Chaoui; K Karl; K Kalache; F Faschingbauer; M Ponnath; A Rempen; P Kozlowski
Journal:  Prenat Diagn       Date:  2015-02-04       Impact factor: 3.050

3.  Can prenatal ultrasound findings predict ambulatory status in fetuses with open spina bifida?

Authors:  J R Biggio; J Owen; K D Wenstrom; W J Oakes
Journal:  Am J Obstet Gynecol       Date:  2001-11       Impact factor: 8.661

4.  A six year study of the antenatal detection of fetal abnormality in six Scottish health boards.

Authors:  N C Smith; C Hau
Journal:  Br J Obstet Gynaecol       Date:  1999-03

5.  Changes in the birth prevalence of selected birth defects after grain fortification with folic acid in the United States: findings from a multi-state population-based study.

Authors:  Mark A Canfield; Julianne S Collins; Lorenzo D Botto; Laura J Williams; Cara T Mai; Russell S Kirby; Kay Pearson; Owen Devine; Joe Mulinare
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2005-10

6.  Hypothesis: the female excess in cranial neural tube defects reflects an epigenetic drag of the inactivating X chromosome on the molecular mechanisms of neural fold elevation.

Authors:  Diana M Juriloff; Muriel J Harris
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2012-07-02

7.  Choline and risk of neural tube defects in a folate-fortified population.

Authors:  Gary M Shaw; Richard H Finnell; Henk J Blom; Suzan L Carmichael; Stein Emil Vollset; Wei Yang; Per M Ueland
Journal:  Epidemiology       Date:  2009-09       Impact factor: 4.822

Review 8.  Not all cases of neural-tube defect can be prevented by increasing the intake of folic acid.

Authors:  Helmut B Heseker; Joel B Mason; Jacob Selhub; Irwin H Rosenberg; Paul F Jacques
Journal:  Br J Nutr       Date:  2008-12-16       Impact factor: 3.718

9.  The early diagnosis of neural tube defects.

Authors:  Z Blumenfeld; E Siegler; M Bronshtein
Journal:  Prenat Diagn       Date:  1993-09       Impact factor: 3.050

10.  Gene-environment interactions in the causation of neural tube defects: folate deficiency increases susceptibility conferred by loss of Pax3 function.

Authors:  Katie A Burren; Dawn Savery; Valentina Massa; Robert M Kok; John M Scott; Henk J Blom; Andrew J Copp; Nicholas D E Greene
Journal:  Hum Mol Genet       Date:  2008-08-26       Impact factor: 6.150

View more
  101 in total

1.  Parental Perceptions of Child Vulnerability in Families of Youth With Spina Bifida: the Role of Parental Distress and Parenting Stress.

Authors:  Colleen F Bechtel Driscoll; Alexa Stern; Diana Ohanian; Nerissa Fernandes; Autumn N Crowe; S Samaduddin Ahmed; Grayson N Holmbeck
Journal:  J Pediatr Psychol       Date:  2018-06-01

2.  Physician views regarding the benefits and burdens of prenatal surgery for myelomeningocele.

Authors:  R M Antiel; C A Collura; A W Flake; M P Johnson; N E Rintoul; J D Lantos; F A Curlin; J C Tilburt; S D Brown; C Feudtner
Journal:  J Perinatol       Date:  2017-06-15       Impact factor: 2.521

3.  Ambulation, lesion level, and health-related quality of life in children with myelomeningocele.

Authors:  Ebru Şeker Abanoz; Meral Özmen; Mine Çalışkan; Gülbin Gökçay; Nur Aydınlı
Journal:  Childs Nerv Syst       Date:  2019-08-19       Impact factor: 1.475

4.  Prenatal Repair of Myelomeningocele and School-age Functional Outcomes.

Authors:  Amy J Houtrow; Elizabeth A Thom; Jack M Fletcher; Pamela K Burrows; N Scott Adzick; Nina H Thomas; John W Brock; Timothy Cooper; Hanmin Lee; Larissa Bilaniuk; Orit A Glenn; Sumit Pruthi; Cora MacPherson; Diana L Farmer; Mark P Johnson; Lori J Howell; Nalin Gupta; William O Walker
Journal:  Pediatrics       Date:  2020-02       Impact factor: 7.124

5.  A Systematic Review of Behavioral Intervention Technologies for Youth With Chronic Health Conditions and Physical and Intellectual Disabilities: Implications for Adolescents and Young Adults With Spina Bifida.

Authors:  Colleen Stiles-Shields; Autumn N Crowe; Colleen F Bechtel Driscoll; Diana M Ohanian; Alexa Stern; Elicia Wartman; Adrien M Winning; Q Eileen Wafford; Emily G Lattie; Grayson N Holmbeck
Journal:  J Pediatr Psychol       Date:  2019-04-01

6.  Health behaviors and disordered eating in adolescents and young adults with spina bifida: results from a national survey.

Authors:  Colleen Stiles-Shields; Grayson N Holmbeck
Journal:  Disabil Rehabil       Date:  2019-04-12       Impact factor: 3.033

7.  Multiple Congenital Anomalies in a Patient with Interstitial 6q26 Deletion.

Authors:  Surasak Puvabanditsin; Emily Negroponte; Peter Jang; Amanda Hedges; Ramnan Kased; Rajeev Mehta
Journal:  Mol Syndromol       Date:  2019-10-22

Review 8.  One-Carbon Metabolism in Health and Disease.

Authors:  Gregory S Ducker; Joshua D Rabinowitz
Journal:  Cell Metab       Date:  2016-09-15       Impact factor: 27.287

9.  Non-neural surface ectodermal rosette formation and F-actin dynamics drive mammalian neural tube closure.

Authors:  Chengji J Zhou; Yu Ji; Kurt Reynolds; Moira McMahon; Michael A Garland; Shuwen Zhang; Bo Sun; Ran Gu; Mohammad Islam; Yue Liu; Tianyu Zhao; Grace Hsu; Janet Iwasa
Journal:  Biochem Biophys Res Commun       Date:  2020-04-02       Impact factor: 3.575

10.  Therapeutic potential of adenovirus-encoding brain-derived neurotrophic factor for spina bifida aperta by intra-amniotic delivery in a rat model.

Authors:  Wei Ma; Xiaowei Wei; Hui Gu; Dan Liu; Wenting Luo; Dong An; Yuzuo Bai; Zhengwei Yuan
Journal:  Gene Ther       Date:  2020-02-24       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.